AzTrials
AzTrials

Cerebral Adrenoleukodystrophy (CALD)Phase 3NCT03852498

A Clinical Study to Assess the Efficacy and Safety of Gene Therapy for the Treatment of Cerebral Adrenoleukodystrophy (CALD)

A Phase 3 study testing Lenti-D in people with Cerebral Adrenoleukodystrophy (CALD), run by Genetix Biotherapeutics Inc. at 8 sites in 6 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to evaluate the efficacy and safety of Lenti-D Drug Product (also known as elivaldogene autotemcel or Skysona, hereafter referred to as eli-cel) after myeloablative conditioning with busulfan and fludarabine in participants with CALD. Read more about this study

Who is it for?
Ages Up to 17 years, men only
Conditions the study is for
Cerebral Adrenoleukodystrophy (CALD)
What is being tested?
Lenti-D
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
35 participants
Where
8 sitesin 6 countries
Study dates
24 Jan 2019to 24 Jul 2023
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Up to 17 years
  • Men only
  • No healthy volunteers
  • Child

Who may be able to join

  • Informed consent is obtained from a competent custodial parent or guardian with legal capacity to execute a local Institutional Review Board (IRB)/independent ethics committee (IEC) approved consent. Informed assent will be sought from capable participants, in accordance with the directive of the IRB/IEC and with local requirements.
  • Males aged 17 years and younger, at the time of parental/guardian consent and, where appropriate, participant assent.
  • Active CALD as defined by:
  • Elevated very long chain fatty acids (VLCFA) values, and
  • Active central nervous system (CNS) disease established by central radiographic review of brain MRI demonstrating: i) Loes score between 0.5 and 9 (inclusive) on the 34-point scale, and ii) Gadolinium enhancement (GdE) on MRI of demyelinating lesions.
  • NFS < or = 1.

Who cannot join

  • Prior receipt of an allogeneic transplant or gene therapy.
  • Use of statins, Lorenzo's Oil, or dietary regimens used to lower VLCFA levels. Note: participants must discontinue use of these medications at time of consent.
  • Receipt of an investigational study drug or procedure within 3 months before Screening that might confound study outcomes. Use of investigational study drugs is prohibited throughout the course of the study.
  • Any conditions that make it impossible to perform MRI studies (including allergies to anesthetics or contrast agents).
  • Hematological compromise as evidenced by:
  • Peripheral blood absolute neutrophil count (ANC) count <1500 cells/ cubic millimeter (mm^3), and either
Show all 21Show fewer
  • Platelet count <100,000 cells/mm^3, or
  • Hemoglobin <10 gram per deciliter (g/dL).
  • Hepatic compromise as evidenced by:
  • Aspartate transaminase (AST) value greater than (>) 2.5 × upper limit of normal (ULN)
  • Alanine transaminase (ALT) value >2.5 × ULN
  • Total bilirubin value >3.0 milligram per deciliter (mg/dL), except if there is a diagnosis of Gilbert's Syndrome and the participant is otherwise stable
  • Baseline estimated glomerular filtration rate <70 milliliter per minute (mL/min)/1.73 square meter (m^2).
  • Cardiac compromise as evidenced by left ventricular ejection fraction <40 percent (%).
  • Immediate family member with a known or suspected Familial Cancer Syndrome.
  • Clinically significant uncontrolled, active bacterial, viral, fungal, parasitic, or prion associated infection.
  • Positive for human immunodeficiency virus type 1 or 2 (HIV-1, HIV-2); hepatitis B virus (HBV); hepatitis C virus (HCV); human T lymphotrophic virus 1 (HTLV-1). (Note that participants who have been vaccinated against HBV [positive for HBV surface antibodies] who are negative for other markers of prior HBV infection [e.g., negative for HBV core Ab] are eligible. Participants with past exposure to HBV [hepatitis B core antibody [HBcAb] -positive and/or hepatitis B e-antigen antibody [HBeAb]-positive] are also eligible for the study provided they have a negative test for HBV DNA. Also note that participants who are positive for anti-hepatitis C Ab are eligible as long as they have a negative hepatitis C viral load).
  • Any clinically significant cardiovascular, hematological, or pulmonary disease, or other disease or condition that would be contraindicated for any of the other study procedures.
  • Absence of adequate contraception for fertile participants.
  • Any contraindications to the use of Granulocyte colony-stimulating factor (G-CSF) or plerixafor during the mobilization of HSCs, and any contraindications to the use of busulfan or fludarabine, including known hypersensitivity to the active substances or to any of the excipients in their formulations.
  • Known hypersensitivity to protamine sulfate.

Trial locations and contacts

8 sites in 6 countries.

8 sites in 6 countries

United States3 sites
  • Boston Children's Hospital/Massachusetts General Hospital

    Boston, Massachusetts, 02215

  • University of Minnesota

    Minneapolis, Minnesota, 55455

  • Lucile Packard Children's Hospital

    Palo Alto, California, 94304

Other trials in United States

France1 site
  • Hôpital Robert Debré

    Paris, 75019

Other trials in France

Germany1 site
  • Universitätsklinikum Leipzig AöR

    Leipzig, 04103

Other trials in Germany

Italy1 site
  • Ospedale Pediatrico Bambino Gesù

    Rome, 00165

Other trials in Italy

Netherlands1 site
  • Prinses Maxima Center

    Utrecht, 3508AB

Other trials in Netherlands

United Kingdom1 site
  • UCL-ICH/Great Ormond Street Hospital

    London, WC1N3JH

Other trials in United Kingdom

About this study

Official title: A Phase 3 Study of Lenti-D Drug Product After Myeloablative Conditioning Using Busulfan and Fludarabine in Subjects ≤17 Years of Age With Cerebral Adrenoleukodystrophy (CALD)

The purpose of this study is to evaluate the efficacy and safety of Lenti-D Drug Product (also known as elivaldogene autotemcel or Skysona, hereafter referred to as eli-cel) after myeloablative conditioning with busulfan and fludarabine in participants with CALD. A participant's blood stem cells will be collected and modified (transduced) using the Lenti-D lentiviral vector encoding human adrenoleukodystrophy protein. After modification (transduction) with the Lenti-D lentiviral vector, the cells will be transplanted back into the participant following myeloablative conditioning. Enrollment and treatment in Study ALD-104 have been completed and further enrollment in this study is not expected, although participants follow-up remains ongoing in the long-term follow-up Study LTF-304 (NCT02698579).

Being tested
Lenti-D
Keywords
Adrenoleukodystrophy, X-linked adrenoleukodystrophy, Gene therapy, Hematopoietic stem cell
Medical subject headings
Adrenoleukodystrophy

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Lenti-DGenetic

    Also called elivaldogene autotemcel, eli-cel

    Participants received a single IV infusion of Lenti-D Drug Product.

Study groups in NCT03852498
Study groupRoleWhat they receive
Lenti-D Drug ProductExperimentalParticipants received a single intravenous (IV) infusion of eli-cel (also referred to as Lenti-D Drug Product) on Day 1 at a dose of > or = 5.0*10^6 CD34+ cells/kilogram (kg). All participants received myeloablative conditioning with busulfan and fludarabine over a number of days prior to drug product infusion.
Receives: Genetic: Lenti-D

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percentage of Participants Who Were Alive and Have None of the 6 Major Functional Disabilities (MFDs) at Month 24

    The MFDs consisted of loss of communication, cortical blindness, tube feeding, total incontinence, wheelchair dependence, complete loss of voluntary movement. Month-24 MFD-Free survival criteria defined as: alive at 24 months post infusion; have not developed any of the MFDs by 24 months post infusion; have not received rescue cell administration or allo-hematopoietic stem cell transplantation (HSCT) by 24 months post infusion; and have not withdrawn from the study or have not been lost to follow-up by 24 months post infusion.

    Measured: At Month 24

  2. Percentage of Participants Who Achieved Neutrophil Engraftment After Drug Product Infusion

    Neutrophil engraftment is defined as achieving 3 consecutive absolute neutrophil count (ANC) laboratory values of >= 0.5x10^9 cells/liter (L) (after initial post-infusion nadir) obtained on different days by 42 days postinfusion of eli-cel (Rel Day 43).

    Measured: By 42 days post-drug infusion

Secondary outcomes (27)
  1. Percentage of Participants Without Gadolinium Enhancement (i.e. GdE-) on Magnetic Resonance Imaging (MRI) at Month 24

    Percentage of participants without Gadolinium Enhancement (i.e. GdE-) on MRI at Month 24 were reported.

    Measured: At Month 24

  2. Number of Participants With Change in Neurologic Function Score (NFS) From Baseline to Month 24

    NFS was a 25-point score used to evaluate the severity of gross neurologic dysfunction in cerebral adrenoleukodystrophy (CALD) by scoring 15 symptoms (functional domains) across 6 categories. Listed here are the 15 symptoms followed by their maximal score out of 25 points: a) Hearing/auditory processing problems-1, b) Aphasia/apraxia-1, c) Loss of communication-3, d) Vision impairment/field cut-1, e) Cortical blindness- 2, f) Swallowing/other central nervous system (CNS) dysfunctions-2, g) Tube feeding-2, h) Running difficulties/hyperreflexia-1, i) Walking difficulties/spasticity/spastic gait (no assistance)-1, j) Spastic gait (needs assistance)-2, k) Wheelchair dependence-2, l) Complete loss of voluntary movement-3, m) Episodes of incontinence -1, n) Total incontinence-2, o) Nonfebrile seizures-1. A score of "0"= absence of clinical signs of cerebral disease.

    Measured: Baseline up to Month 24

  3. Number of Participants Who Achieved Stable NFS at Month 24

    Stable NFS was defined as maintaining an NFS <=4 without an increase of >3 from Baseline. Number of participants who achieved stable NFS at Month 24 were reported.

    Measured: At Month 24

  4. Major Functional Disability (MFD)-Free Survival Rate

    MFD-free survival rate was defined as percentage of participants from drug product infusion to either second transplant, MFD, or death due to any cause, whichever occurs first. MFD-free survival rate was analyzed using Kaplan-Meier Analysis. Kaplan-Meier estimated MFD-free survival rate at 24 months after Lenti-D drug infusion was reported.

    Measured: At 24 months after Lenti-D drug infusion

  5. Overall Survival Rate

    Overall survival rate was defined as percentage of participants alive from date of Lenti-D drug product infusion (Day 1) to date of death of all causes. Overall survival rate was censored at the date of last visit if the subject were alive. Participants who are alive were censored at the date of last contact. Overall survival rate was analyzed using Kaplan-Meier Analysis.

    Measured: At 24 months after Lenti-D drug infusion

  6. Median Detectable Vector Copy Number (VCN) in Peripheral Blood Cells by Month 6

    Presence of vector sequences in the genome of cells derived from the originally transduced HSC indicates the presence of transduced cells amongst the HSC precursors. The presence of vector sequences was evaluated throughout the study in whole blood, in selected subpopulations of blood cells (including CD14+ cells), and in bone marrow when indicated. The presence of vector sequences in the genomic DNA of cells was detected using quantitative polymerase chain reaction (qPCR), and results were expressed as vector copy number (VCN; vector copies per diploid genome, c/dg).

    Measured: By Month 6 post-transplant

  7. Time to Neutrophil Engraftment (NE) After Drug Product Infusion

    Neutrophil engraftment is defined as achieving 3 consecutive absolute neutrophil count (ANC) laboratory values of >= 0.5 x 10^9 cells/liter (L) (after initial post-infusion nadir) obtained on different days by 42 days post-infusion of eli-cel (Rel Day 43). Time to neutrophil engraftment after drug product infusion was reported.

    Measured: By 42 days post-drug infusion

  8. Percentage of Participants With Platelet Engraftment by Month 24

    Platelet engraftment was defined as achieving 3 consecutive unsupported platelet counts of >=20 x 10^9 cells/L (after initial post-infusion nadir) obtained on different days while no platelet transfusions were administered for 7 days immediately preceding and during the evaluation period. The first Day of 3 consecutive platelet counts >=20 x 10^9 cells/L was considered the Day of platelet engraftment.

    Measured: By Month 24

  9. Time to Platelet Engraftment Post-drug Product Infusion

    Platelet Engraftment was defined as achieving 3 consecutive unsupported platelet counts of > or =20 x 10^9 cells/L (after initial post-infusion nadir) obtained on different days while no platelet transfusions were administered for 7 days immediately preceding and during the evaluation period. The first day of 3 consecutive platelet counts >=20 x 10^9 cells/L was the day of PE. Time to platelet engraftment post-drug product infusion by Month 24 was reported.

    Measured: By Month 24

  10. Percentage of Participants With Loss of Neutrophil Engraftment Post-drug Product Infusion by Month 24

    Participants were considered to have primary engraftment failure if they did not achieve NE by Relative Day 43. A participant was considered to have secondary engraftment failure if they achieved and then subsequently lost NE by the Month 24, i.e., if they met both the conditions; Achieved NE by Relative Day 43 as defined above and had sustained decline in ANC to < 0.5 x 10^9 cells/L for 3 consecutive measurements on different days after Relative Day 43, without alternate etiology. First day of the 3 consecutive ANC decline to < 0.5 x 10^9 cells/L was considered the day of secondary engraftment failure. Percentage of participants with both primary or secondary loss of neutrophil engraftment at Month 24 were reported.

    Measured: By Month 24

  11. Percentage of Participants Who Underwent a Subsequent Allo- Hematopoietic Stem Cell Transplantation (HSCT) Infusion by Month 24

    Percentage of participants who have undergone a subsequent allo-HSCT infusion by Month 24 were reported.

    Measured: By Month 24

  12. Percentage of Participants Who Experienced Either Acute (>= Grade 2) or Chronic Graft Versus Host Disease (GVHD) at Month 24

    Acute GVHD graded on the Acute GVHD Grading Scale (1-4): Grade 1 is characterized as mild disease, Grade 2 as moderate, Grade 3 as severe (involvement of any organ system), and Grade 4 as life-threatening; chronic GVHD was determined by the Investigator. GVHD was seen after an eli-cel participant received a subsequent allogeneic hematopoietic stem cell transplant. No GVHD was seen in participants who did not receive allogeneic stem cell transplants. Grade 2 non-serious GVHD was reported in a participant who received allogeneic transplant post eli-cel infusion. Percentage of participants who experienced either acute (>= Grade 2) or chronic GVHD at Month 24 were reported.

    Measured: At Month 24

  13. Percentage of Participants Who Experienced >= Grade 2 Acute Graft Versus Host Disease (GVHD) by Month 24

    Acute GVHD graded on the Acute GVHD Grading Scale (1-4): Grade 1 is characterized as mild disease, Grade 2 as moderate, Grade 3 as severe (involvement of any organ system), and Grade 4 as life-threatening; Acute GVHD was determined by the Investigator. GVHD was seen after an eli-cel participant received a subsequent allogeneic hematopoietic stem cell transplant. No GVHD was seen in participants who did not receive allogeneic stem cell transplants. Grade 2 non-serious GVHD was reported in a participant who received allogeneic transplant post eli-cel infusion. Percentage of participants who experienced >= Grade 2 Acute GVHD at Month 24 were reported.

    Measured: By Month 24

  14. Percentage of Participants Who Experienced Chronic GVHD by Month 24

    Chronic GVHD graded on the Chronic GVHD Grading Scale as limited or extensive. Chronic GVHD was determined by the Investigator. No chronic GVHD was observed in any participants. Acute GVHD was seen after an eli-cel participant received a subsequent allogeneic hematopoietic stem cell transplant. No GVHD was seen in participants who did not receive allogeneic stem cell transplants. Grade 2 non-serious GVHD was reported in a participant who received allogeneic transplant post eli-cel infusion. Percentage of participants who experienced chronic GVHD by Month 24 were reported.

    Measured: By Month 24

  15. Percentage of Participants Who Experienced Transplant-related Mortality Through 100 and 365 Days Post-drug Product Infusion

    Transplant-related mortality was determined by the investigator and summarized for the following intervals: from Rel Day 1 through 100 days post-drug product infusion (Rel Day 101) and from Rel Day 1 through 365 days post-drug product infusion (Rel Day 366). Percentage of participants who experienced transplant-related mortality through 100 and 365 days post-drug product infusion were reported.

    Measured: From time of drug product infusion through 100 and 365 days post-drug product infusion

  16. Percentage of Participants With Clinical >= Grade 3 Adverse Events (AEs), All Investigational Medicinal Product-related AEs, All Serious Adverse Events (SAEs), and >= Grade 3 Infections

    Adverse event was defined as any untoward medical occurrence associated with the use of a drug product in participants, whether or not considered drug related. SAE was any AE, occurring at any dose and regardless of causality, that resulted in death, was life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, a congenital anomaly/birth defect, or was considered an important medical event that may jeopardize the subject and may require medical or surgical intervention to prevent an outcome listed previously. Percentage of participants with clinical >= Grade 3 AEs, all investigational medicinal product-related AEs, all serious adverse events (SAEs), and >= Grade 3 infections were reported.

    Measured: From date of informed consent up to Month 24

  17. Number of Participants With >= Grade 3 Prolonged Cytopenia on or After Rel Day 60 And Rel Day 100

    Number of participants with >= Grade 3 prolonged cytopenia (i.e., decreased platelet counts, decreased neutrophil counts, and/or decreased hemoglobin counts) on or after Rel Day 60 and Rel Day 100 were reported.

    Measured: Prolonged cytopenias occurring on or after Rel Day 60 and Rel Day 100 following drug product infusion

  18. Percentage of Participants With Potentially Clinically Significant Changes in Laboratory Parameters by Month 24

    Laboratory parameters included Hematology (Leukocytes [with a threshold range <4.0 x 10^9/L, >=18 x 10^9/L], Neutrophils [<1.0 x 10^9/L], Erythrocytes [<=3.0 x 10^12/L], Platelets [<=75 x 10^9/L]); Clinical chemistry (Sodium [<=126 millimoles per liter (mmol/L), >=156 mmol/L], Potassium [<=3 mmol/L, >=6 mmol/L], Glucose [<=3.0 mmol/L]), Renal (Urea Nitrogen [>=10.7 mmol/L], Creatinine [>=150 umol/L]) and liver (Alanine Aminotransferase [ALA]. Aspartate Aminotransferase [ASA], Alkaline Phosphatase [AP] with threshold range of >=3 x upper limit of normal (ULN), Bilirubin [>=34.2 micromoles per liter (umol/L)]). Clinical significance was decided by investigator.

    Measured: From Day 1 to Month 24

  19. Number of Emergency Room Visits (Post-Neutrophil Engraftment) by Month 24

    Number of emergency room visits (post-neutrophil engraftment) up to Month 24 were reported.

    Measured: From Post-Neutrophil Engraftment up to Month 24

  20. Median Number of Emergency Room Visits (Post-Neutrophil Engraftment) by Month 24

    Median number of emergency room visits (post-neutrophil engraftment) up to Month 24 were reported.

    Measured: From Post-Neutrophil Engraftment up to Month 24

  21. Number of In-patient Hospitalizations (Post-Neutrophil Engraftment) by Month 24

    Number of In-patient hospitalizations (post-neutrophil engraftment) by Month 24 were reported.

    Measured: From Post-Neutrophil Engraftment up to Month 24

  22. Median Number of In-patient Hospitalizations (Post-Neutrophil Engraftment) by Month 24

    Median number of In-patient hospitalizations (post-neutrophil engraftment) by Month 24 were reported.

    Measured: From post-neutrophil engraftment up to Month 24

  23. Duration of In-patient Hospitalizations (Post-Neutrophil Engraftment) up to Month 24

    Duration of in-patient hospitalizations was calculated as: Duration = (Date of hospital discharge) - (Date of hospital admission before NE) + 1. Duration of In-patient hospitalizations (post-neutrophil engraftment) up to Month 24 was reported. The range of in-patient hospitalizations is influenced by hospital stays for participants who received allogeneic stem cell transplants.

    Measured: From post-neutrophil engraftment up to Month 24

  24. Number of Intensive Care Units (ICU) Stays (Post-neutrophil Engraftment) by Month 24

    Number of ICU Stays (Post-neutrophil Engraftment) By Month 24 were reported.

    Measured: From post-neutrophil engraftment up to Month 24

  25. Duration of ICU Stays (Post-neutrophil Engraftment) by Month 24

    Duration of ICU Stays was calculated as: Duration = (Date of hospital discharge) - (Date of hospital admission before NE) + 1. Duration of ICU Stays (Post-neutrophil Engraftment) by Month 24 was reported.

    Measured: From post-neutrophil engraftment up to Month 24

  26. Number of Participants Who Tested Positive and Negative for Vector-Derived Replication Competent Lentivirus (RCL) Detected by Month 24

    Number of participants who tested positive and negative for vector-derived RCL detected at Month 24 were reported. Screening of participant's blood samples for RCL at Month 24 following Lenti-D Drug infusion was performed, with the more rigorous co-culture assays used to distinguish any false positives as applicable.

    Measured: By Month 24

  27. Number of Participants With Insertional Oncogenesis by Month 24

    Insertional oncogenesis included myelodysplastic syndrome, leukemia, lymphoma. Number of participants with insertional oncogenesis at Month 24 were reported.

    Measured: By Month 24 post-transplant

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 Feb 2019
  2. Study start24 Jan 2019
  3. Primary completion24 Jul 2023
  4. Study completion24 Jul 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
35 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03852498
Sponsor's protocol ID
ALD-104
Other IDs
2018-001145-14, 2018
Status last verified
Apr 2024
First submitted
13 Feb 2019
Last updated
24 May 2024
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: Bluebird bio is committed to transparency. Appropriately de-identified patient-level datasets and supporting documents may be shared following attainment of applicable marketing approvals associated with this study and consistent with criteria established by bluebird bio and/or industry best practices in order to maintain the privacy of study participants. For enquiries, please contact bluebird bio at datasharing@bluebirdbio.com.

Publications

  • Duncan CN, Bledsoe JR, Grzywacz B, Beckman A, Bonner M, Eichler FS, Kuhl JS, Harris MH, Slauson S, Colvin RA, Prasad VK, Downey GF, Pierciey FJ, Kinney MA, Foos M, Lodaya A, Floro N, Parsons G, Dietz AC, Gupta AO, Orchard PJ, Thakar HL, Williams DA. Hematologic Cancer after Gene Therapy for Cerebral Adrenoleukodystrophy. N Engl J Med. 2024 Oct 10;391(14):1287-1301. doi: 10.1056/NEJMoa2405541.

    PubMed 39383458

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Lenti-D in people with Cerebral Adrenoleukodystrophy (CALD), run by Genetix Biotherapeutics Inc. at 8 sites in 6 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 21 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 24 May 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 8 sites in United States, France, Germany, Italy, Netherlands and 1 more country. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 24 May 2024). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percentage of Participants Who Were Alive and Have None of the 6 Major Functional Disabilities (MFDs) at Month 24 (time frame: At Month 24). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03852498, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 May 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in